Agenus (AGEN)
(Delayed Data from NSDQ)
$15.60 USD
+0.21 (1.36%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $15.61 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
AGEN 15.60 +0.21(1.36%)
Will AGEN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AGEN
IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
AGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates
Other News for AGEN
Promising Clinical Outcomes for Agenus’s CRC Treatment Support Buy Rating
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
Agenus reports 'significant' tumor reductions in neoadjuvant MSS colon cancer
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors